Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomma Lab InternacionalB de CVMEX:LABB +3.36%66 Intrinsic Value: Projected FCF is MXN28.70 as of Jul. 25, 2026, which is 100% below its 10-year median of 0.99. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.22 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 632 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 91.46% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Intrinsic Value: Projected FCF or its related term are showing as below:
MEX:LABB'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.5 Med: 0.99 Max: 2.51
Current: 0.5
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Genomma Lab InternacionalB de CV was 2.51. The lowest was 0.50. And the median was 0.99.
MEX:LABB's Price-to-Projected-FCF is ranked better than 91.46% of 632
companies
in the Drug Manufacturers industry
Industry Median: 1.53
vs MEX:LABB: 0.50
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Genomma Lab InternacionalB de CV's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
14.47
/
28.695121064347
=
0.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Intrinsic Value: Projected FCF Related Terms
Genomma Lab InternacionalB de CV Intrinsic Value: Projected FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Intrinsic Value: Projected FCF Chart
MEX:LABB vs ZTS, UTHR, VTRS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Price-to-Projected-FCF falls into.
Genomma Lab InternacionalB de CV Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of MXN28.70 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Intrinsic Value: Projected FCF of MXN28.70 as of Jul. 25, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 2799% above median its historical median of 0.99. Over the past decade, Genomma Lab InternacionalB de CV's Intrinsic Value: Projected FCF has ranged from 0.50 to 2.51. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #54 out of 632 companies in the Drug Manufacturers industry, placing it in the top 8.5%.
Is Genomma Lab InternacionalB de CV's Intrinsic Value: Projected FCF too high?
Genomma Lab InternacionalB de CV's current Intrinsic Value: Projected FCF of MXN28.70 is 2799% above median its 10-year median of 0.99. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 2.51. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #54 out of 632 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Intrinsic Value: Projected FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #54 out of 632 companies for Intrinsic Value: Projected FCF. This places Genomma Lab InternacionalB de CV in the top 9% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.53. Historically, Genomma Lab InternacionalB de CV's own Intrinsic Value: Projected FCF has ranged from 0.50 to 2.51 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.53, based on 632 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Intrinsic Value: Projected FCF is MXN28.70, which is 2799% above median its own 10-year median of 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.22, compared to a current price of MXN14.47 — trading 16% below its estimated fair value. The current Intrinsic Value: Projected FCF is MXN28.70, which is 2799% above median its 10-year median of 0.99. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Intrinsic Value: Projected FCF is MXN28.70 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.47 is trading 16% below its estimated GF Value™ of MXN17.22.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Intrinsic Value: Projected FCF: MXN28.70 (2799% above median its 10-year median of 0.99)
GF Value™: MXN17.22 vs. price of MXN14.47 (16% below fair value)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
